Johnson & Johnson’s Janssen has announced their results from Phase III ECLIPSE study, which show superior long-term efficacy of Tremfya (guselkumab) compared with Cosentyx (secukinumab) in adults with moderate to severe plaque psoriasis. The data, which was published in The Lancet, showed a significantly higher proportion of Tremfya patients achieved a PASI 90 response at Week
Eli Lilly and Company (Lilly) has commenced the IXORA-R head-to-head (H2H) clinical trial to investigate the efficacy and safety of ixekizumab when compared to guselkumab to treat adult patients with moderate-to-severe plaque psoriasis. Roughly 960 patients are expected to be included in the 24-week, multicentre, randomised, blinded, parallel-group trial. The trial’s primary objective is the
Novartis has recently released trial data showing that Cosentyx was shown to be significantly more effective in treating patients with psoriasis when compared to the Johnson & Johnson’s rival biologic Stelara. According to the published results from the head-to-head CLARITY study, 66.5% of patients treated with Cosentyx achieved the primary endpoint PASI 90 (a 90%
